CPA
SWTX

Capital Performance Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Capital Performance Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$96 – 2388
2024
Q3 		$96 Buy
+3
New +$112 ﹤0.01% 2704

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Performance Advisors's SWTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 3 shares — an estimated $96 sold.

Capital Performance Advisors first reported a position in SWTX in Q3 2024 and held it in 1 quarter. The position peaked at $96 in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 3 SpringWorks Therapeutics shares in Q4 2024, an estimated $96.
  • Capital Performance Advisors first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's SpringWorks Therapeutics position peaked at $96 in Q3 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.